Personalized Dosimetry in the Context of Radioiodine Therapy for Differentiated Thyroid Cancer

Massimiliano Pacilio; Miriam Conte; Viviana Frantellizzi; Maria Silvia De Feo; Antonio Rosario Pisani; Andrea Marongiu; Susanna Nuvoli; Giuseppe Rubini; Angela Spanu; Giuseppe De Vincentis

doi:10.3390/diagnostics12071763

Diagnostics (Jul 2022)

Personalized Dosimetry in the Context of Radioiodine Therapy for Differentiated Thyroid Cancer

Massimiliano Pacilio,
Miriam Conte,
Viviana Frantellizzi,
Maria Silvia De Feo,
Antonio Rosario Pisani,
Andrea Marongiu,
Susanna Nuvoli,
Giuseppe Rubini,
Angela Spanu,
Giuseppe De Vincentis

Affiliations

Massimiliano Pacilio: Medical Physics Department, “Policlinico Umberto I” University Hospital, 00161 Rome, Italy
Miriam Conte: Department of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza University of Rome, 00161 Rome, Italy
Viviana Frantellizzi: Department of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza University of Rome, 00161 Rome, Italy
Maria Silvia De Feo: Department of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza University of Rome, 00161 Rome, Italy
Antonio Rosario Pisani: Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, 70121 Bari, Italy
Andrea Marongiu: Unit of Nuclear Medicine, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy
Susanna Nuvoli: Unit of Nuclear Medicine, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy
Giuseppe Rubini: Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, 70121 Bari, Italy
Angela Spanu: Unit of Nuclear Medicine, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy
Giuseppe De Vincentis: Department of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza University of Rome, 00161 Rome, Italy

DOI: https://doi.org/10.3390/diagnostics12071763
Journal volume & issue: Vol. 12, no. 7
p. 1763

Abstract

Read online

The most frequent thyroid cancer is Differentiated Thyroid Cancer (DTC) representing more than 95% of cases. A suitable choice for the treatment of DTC is the systemic administration of 131-sodium or potassium iodide. It is an effective tool used for the irradiation of thyroid remnants, microscopic DTC, other nonresectable or incompletely resectable DTC, or all the cited purposes. Dosimetry represents a valid tool that permits a tailored therapy to be obtained, sparing healthy tissue and so minimizing potential damages to at-risk organs. Absorbed dose represents a reliable indicator of biological response due to its correlation to tissue irradiation effects. The present paper aims to focus attention on iodine therapy for DTC treatment and has developed due to the urgent need for standardization in procedures, since no unique approaches are available. This review aims to summarize new proposals for a dosimetry-based therapy and so explore new alternatives that could provide the possibility to achieve more tailored therapies, minimizing the possible side effects of radioiodine therapy for Differentiated Thyroid Cancer.

Published in Diagnostics

ISSN: 2075-4418 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Medicine (General)
Website: http://www.mdpi.com/journal/diagnostics

About the journal

Abstract

Keywords